DeepMed Research

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Biological: FLU Q-PAN H5N8 375_B
Biological: FLU Q-PAN H5N8 375_A
Biological: FLU Q-PAN H5N8 750_B
Biological: FLU Q-PAN H5N8 750_A

First Posted Date: 2023-08-04

Last Posted Date: 2025-02-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 518

Registration Number: NCT05975840

Locations: 🇺🇸
GSK Investigational Site, Norfolk, Virginia, United States

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

Phase 1

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: mRNA-CR-04 vaccine 10μg
Biological: mRNA-CR-04 vaccine 30μg
Biological: mRNA-CR-04 vaccine 100μg
Biological: mRNA-CR-04 vaccine 3μg
Drug: Placebo

First Posted Date: 2023-08-02

Last Posted Date: 2024-03-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 72

Registration Number: NCT05972993

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

Phase 3

Completed

Conditions: Respiratory Syncytial Viruses
Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA investigational vaccine
Biological: HZ/su vaccine

First Posted Date: 2023-07-28

Last Posted Date: 2025-04-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 530

Registration Number: NCT05966090

Locations: 🇨🇦
GSK Investigational Site, Toronto, Canada

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

Phase 2

Active, not recruiting

Conditions: SARS-CoV-2

Interventions: Biological: CV0701 Bivalent High dose
Biological: CV0701 Bivalent Medium dose
Biological: CV0701 Bivalent Low dose
Biological: Control vaccine
Biological: CV0801 Monovalent
Biological: CV0601 Monovalent High dose

First Posted Date: 2023-07-25

Last Posted Date: 2024-03-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 675

Registration Number: NCT05960097

Locations: 🇦🇺
GSK Investigational Site, Tarragindi, Australia

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

Phase 2

Active, not recruiting

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA Investigational Vaccine

First Posted Date: 2023-06-27

Last Posted Date: 2025-05-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 387

Registration Number: NCT05921903

Locations: 🇪🇸
GSK Investigational Site, Santander, Spain

A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Biological: Belimumab
Drug: Standard of care

First Posted Date: 2023-06-23

Last Posted Date: 2025-04-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT05917288

Locations: 🇨🇳
GSK Investigational Site, Suzhou, China

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA investigational vaccine
Biological: PCV20

First Posted Date: 2023-05-30

Last Posted Date: 2025-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1113

Registration Number: NCT05879107

Locations: 🇪🇸
GSK Investigational Site, Valencia, Spain

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Phase 2

Recruiting

Conditions: Scleroderma, Systemic
Systemic Sclerosis Associated Interstitial Lung Disease

Interventions: Other: Placebo
Biological: Belimumab

First Posted Date: 2023-05-26

Last Posted Date: 2025-04-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 300

Registration Number: NCT05878717

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Phase 3

Recruiting

Conditions: Neoplasms, Colon
Colonic Neoplasms

Interventions: Drug: CAPEOX
Biological: Dostarlimab
Drug: FOLFOX

First Posted Date: 2023-05-11

Last Posted Date: 2024-08-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 711

Registration Number: NCT05855200

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Phase 2

Terminated

Conditions: Pain
Osteoarthritis, Knee

Interventions: Drug: GSK3858279
Drug: Placebo

First Posted Date: 2023-05-03

Last Posted Date: 2025-04-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 314

Registration Number: NCT05838742

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy